Louisa Hoes
Cancers will increasingly meet the definition of ‘rare’ in terms of the molecular profiles that make each tumor unique. The more research we can do into this, the better we will be able to offer patients personalized treatment in the future. Whole Genome Sequencing and studies like DRUP are making an important contribution to this.
Back to newsMore news
GLOW: working toward more treatment options for glioblastoma
The outlook for patients with glioblastoma has been unfavorable for years, and treatment options remain limited. That is a reason …
In search of the optimal treatment strategy for glioblastoma
Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …
Whole Genome Sequencing for cancer diagnostics clinically validated
Scientific research has demonstrated that Whole Genome Sequencing (WGS) is at least as reliable as routine diagnostic procedures. Clinical Molecular …
We want to extract the maximum amount of information from the patient’s tumor. This DNA test is the The complete DNA test is the best available tool to extract the maximum amount of information from the patient’s tumor. We only need one tissue sample with sufficient tumor cells. We literally analyze the entire genome, including parts of the DNA that show mutations of which we don’t yet know the importance. This test is tumor-independent and future-proof. These are the two most important advantages of WGS.